Drug Trial Radar · NCT07043725
A Clinical Study of Neoadjuvant Treatment With TQB2102 for Injection for Human Epidermal Growth Factor Receptor 2 (HER2) Positive Breast Cancer
Last checked: Nov 19, 2026Latest source record: Nov 2, 2026 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Recruiting
Enrollment
544
Planned (sponsor's estimate)
Start
Sep 15, 2025
Primary completion
Sep 2027
Study completion Sep 2029
Sponsor
- Lead sponsor
- Chia Tai Tianqing Pharmaceutical Group Nanjing Shunxin Pharmaceutical Co., Ltd.Industry
- Sponsor type
- Industry
- First posted
- Jun 29, 2025
Design
- Study type
- Interventional
- Phase
- Phase 3
- Allocation
- Randomized
- Model
- Parallel
- Masking
- None
- Primary purpose
- Treatment
- FDA-regulated drug
- No
- Who can join
- All sexes, from 18 years, up to 75 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
This is a randomized, open, positive drug control, multi center phase III study. Through the evaluation of tpCR, bpCR, ORR, EFS, IDFS, OS, AEs and other indicators, it proves the effectiveness and safety of TQB2102 for injection versus Active Comparator in the neoadjuvant treatment of HER2 positive breast cancer patients. About 544 HER2 positive early or locally advanced breast cancer patients will be randomly assigned to TQB2102 treatment group (test group) or Docetaxel combined with Carboplatin, Trastuzumab, and Pertuzumab (TCbHP) (Active Comparator) in a 1:1 ratio. The subjects in the test group will receive 8 cycles of study drug treatment, and the subjects in the control group will receive 6 cycles of study drug treatment, followed by surgery for breast cancer, and disease recurrence visit and survival visit after surgery.
Conditions
- HER2-positive Breast Cancer
Interventions
TQB2102 for injectionDrug
TQB2102 for injection is a HER2 dual-antibody-drug Conjugate (ADC)
Trastuzumab injection and Pertuzumab Injection and Docetaxel Injection and Carboplatin InjectionDrug
TCbHP is a commonly used chemotherapy scheme for HER2 positive breast cancer. H represents Trastuzumab injection, P represents Pertuzumab Injection, T represents Docetaxel injection and C represents Carboplatin injection.
Primary outcomes
What the sponsor says the trial is designed to measure.
- Rate of total physiological complete response (tpCR) evaluated by Independent Review Committee (IRC)Time frame: Up to 26 months after study start
Locations
77 sites in 1 country. Site status is shown where the registry gives one.
The First Affiliated Hospital of Bengbu Medical University
Bengbu, Anhui, China · Not yet recruiting
Anhui Provincial Cancer Hospital
Hefei, Anhui, China · Not yet recruiting
The First Affiliated Hospital of Wannan Medical University
Wuhu, Anhui, China · Not yet recruiting
Peking Union Medical College Hospital
Beijing, Beijing Municipality, China · Not yet recruiting
Beijing Cancer Hospital
Beijing, Beijing Municipality, China · Not yet recruiting
The First Affiliated Hospital of Chongqing Medical University
Chongqing, Chongqing Municipality, China · Not yet recruiting
The Second Affiliated Hospital of Chongqing Medical University
Chongqing, Chongqing Municipality, China · Not yet recruiting
The Cancer Hospital Affiliated to Chongqing University, Chongqing Cancer Hospital, Chongqing Cancer Research Institute, and Chongqing Cancer Center
Chongqing, Chongqing Municipality, China · Not yet recruiting
The First Hospital Affiliated to Army Medical University
Chongqing, Chongqing Municipality, China · Not yet recruiting
Quanzhou First Hospital
Quanzhou, Fujian, China · Not yet recruiting
The Second Affiliated Hospital of Fujian Medical University
Quanzhou, Fujian, China · Not yet recruiting
Zhongshan Hospital Xiamen university
Xiamen, Fujian, China · Not yet recruiting
ZhangZhou Municipal Hospital of Fujian Province
Zhangzhou, Fujian, China · Not yet recruiting
The First Hospital of Lanzhou University
Lanzhou, Gansu, China · Not yet recruiting
Gansu Provincial Academic Institute for Medical Research, Gansu Provincial Cancer Hospital
Lanzhou, Gansu, China · Not yet recruiting
Gansu Wuwei Tumour Hospital
Wuwei, Gansu, China · Not yet recruiting
Sun Yat-sen Memorial Hospital, Sun Yat-sen University
Guangzhou, Guangdong, China · Not yet recruiting
The Second Affiliated Hospital of Guangzhou Medical University
Guangzhou, Guangdong, China · Not yet recruiting
Meizhou People's Hospital
Meizhou, Guangdong, China · Not yet recruiting
Shantou Central Hospital
Shantou, Guangdong, China · Not yet recruiting
Guigang City People's Hospital
Guigang, Guangxi, China · Not yet recruiting
Guangxi Cancer Institutu (Guangxi Cancer Hospital, Guangxi Medical University Cancer Hospital, Guangxi Cancer Center)
Nanning, Guangxi, China · Not yet recruiting
The First Affiliated Hospital of Guangxi Medical University
Nanning, Guangxi, China · Not yet recruiting
The Affiliated Cancer Hospital of Guizhou Medical University
Guiyang, Guizhou, China · Not yet recruiting
Guizhou Provincial People's Hospital
Guiyang, Guizhou, China · Not yet recruiting
Cangzhou Central Hospital
Cangzhou, Hebei, China · Not yet recruiting
First Hospital of QinHuangDao
Qinhuangdao, Hebei, China · Not yet recruiting
The Fourth Hospital of Hebei Medical University
Shijiazhuang, Hebei, China · Not yet recruiting
Jiamusi Cancer Hospital
Jiamusi, Heilongjiang, China · Recruiting
Harbin Medical University Cancer Hospital
Harbin, Heilongjinag, China · Not yet recruiting
Anyang Tumor Hospital
Anyang, Henan, China · Not yet recruiting
The People's Hospital of Anyang City
Anyang, Henan, China · Not yet recruiting
The First Affiliated Hospital of Henan University of Science and Technology
Luoyang, Henan, China · Not yet recruiting
The First Affiliated Hospital of Xinxiang Medical University
Xinxiang, Henan, China · Not yet recruiting
The First Affiliated Hospital of Zhengzhou University
Zhengzhou, Henan, China · Not yet recruiting
Union Hospital, Tongji Medical College, Huazhong University of Science and Technology
Wuhan, Hubei, China · Not yet recruiting
Zhongnan Hospital of Wuhan University
Wuhan, Hubei, China · Not yet recruiting
The Second Xiangya Hospital of Central South University
Changsha, Hunan, China · Not yet recruiting
Xiangya Hospital Central South University
Changsha, Hunan, China · Not yet recruiting
The First Affiliated Hospital of University of South China
Hengyang, Hunan, China · Not yet recruiting
Showing 40 of 77 sites, US sites first. The full list is on the registry record.
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.